Sector News

NICE final guidance backs Pfizer’s Lorviqua

May 14, 2020
Life sciences

The National Institute for Health and Care Excellence (NICE) has published guidance recommending the use of Pfizer’s Lorviqua (lorlatinib) for a certain form of lung cancer on the NHS.

The drug has been recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor; or crizotinib and at least one other ALK tyrosine kinase inhibitor.

Lorviqua, which is also an ALK tyrosine kinase inhibitor, has not been compared directly with other drugs. But according to NICE, analyses indirectly comparing the drug with platinum doublet chemotherapy (PDC) and atezolizumab with bevacizumab, carboplatin and paclitaxel (ABCP) suggest that people who take Lorviqua experience benefits in disease progression and survival.

Moreover, the drug meets NICE’s criteria to be considered a life-extending treatment at the end of life and, while cost-effectiveness remains uncertain, the most likely estimates are within what the Institute normally considers an acceptable use of NHS resources, it said.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.